ArticleFrontiers in neurology2025
Comparative efficacy of moxibustion as an add-on treatment with different durations for diabetic peripheral neuropathy: study protocol for a randomized controlled trial.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06330233 (Construction of Key Technology and Study of the Effect Mechanism of Moxibustion in the Treatment of Diabetic Peripheral Neuropathy Based on Optimal Selection of Acupoints and Moxibustion Volume), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Construction of Key Technology and Study of the Effect Mechanism of Moxibustion in the Treatment of Diabetic Peripheral Neuropathy Based on Optimal Selection of Acupoints and Moxibustion Volume
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic Peripheral Neuropathy (DPN) can markedly diminish patients' quality of life. Current treatments provide limited relief, driving interest in non-invasive options such as moxibustion. Moxibustion, a technique rooted in acupuncture, shows promise for managing pain. However, it lacks standardized protocols for treating DPN, especially concerning moxibustion duration, and its effectiveness for DPN is not well-supported by evidence. Thus, this study seeks to identify the optimal moxibustion duration to relieve DPN symptoms and enhance nerve function, filling an important gap in clinical practice. Methods: Participants will be randomly allocated to three clinical centers, with 30 individuals at each center, and evenly divided among the conventional treatment group, the 15-min moxibustion group, and the 30-min moxibustion group. The conventional treatment group will be administered mecobalamin and epalrestat for a duration of 4 weeks, while the moxibustion groups will receive moxubustion as an add-on therapy treatment twice a week over the same period. The duration of moxibustion differs from the 15-min group, while the procedure remains consistent across the moxibustion groups. The primary outcome is total clinical effectiveness. The second outcomes include electrophysiological examination, the Toronto Clinical Scoring System (TCSS), the Visual Analogue Scale (VAS), the Traditional Chinese Medicine Syndrome Score Scale (TCMS), and infrared thermography testing. The outcomes will be assessed during the baseline period, after the 8th treatment, and at the one-month follow-up. Conclusion: This trial aims to identify the optimal moxibustion duration for DPN symptom relief and nerve function improvement, offering evidence for standardized clinical protocols. The findings could enhance treatment efficacy, reduce adverse effects, and alleviate DPN's socio-economic burden. Clinical trial registration: https://clinicaltrials.gov/, NCT06330233.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.